Similar articles

• Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.

  Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Mauri D, et al. J Natl Cancer Inst. 2006 Sep 20;98(18):1285-91. doi: 10.1093/jnci/djj357. J Natl Cancer Inst. 2006. PMID: 16985247
• [Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].

  Kahán Z. Kahán Z. Magy Onkol. 2008 Jun;52(2):225-6. doi: 10.1556/MOnkol.52.2008.2.11. Magy Onkol. 2008. PMID: 18640899 Hungarian. No abstract available.
• Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.

  Dixon JM. Dixon JM. Expert Rev Anticancer Ther. 2008 Mar;8(3):453-63. doi: 10.1586/14737140.8.3.453. Expert Rev Anticancer Ther. 2008. PMID: 18366292 Review.
• [Aromatase inhibitors in the adjuvant therapy of breast cancer].

  Bauerschlag D, Schem C, Maass N, Jonat W. Bauerschlag D, et al. Gynakol Geburtshilfliche Rundsch. 2005 Jun;45(3):132-6. doi: 10.1159/000085193. Gynakol Geburtshilfliche Rundsch. 2005. PMID: 15990437 German.
• Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.

  Wheler J, Johnson M, Seidman A. Wheler J, et al. Semin Oncol. 2006 Dec;33(6):672-80. doi: 10.1053/j.seminoncol.2006.08.018. Semin Oncol. 2006. PMID: 17145347 Review.